DEST.L Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 19:06):

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom...

Stats
Šios dienos apimtis	1.54M
Vidutinė apimtis	571 769
Rinkos kapitalizacija	15.49M
EPS	£0 ( 2024-04-10 )
Last Dividend	£0 ( N/A )
Next Dividend	£0 ( N/A )
P/E	-2.03
ATR14	£0.295 (1.82%)

Tūris Koreliacija

Ilgas: -0.08 (neutral)

Trumpas: -0.64 (weak negative)

Signal:(54.041) Neutral

Destiny Pharma PLC Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
WINE.L	0.9
GHT.L	0.889
INDV.L	0.883
DPEU.L	0.873
ONC.L	0.859
MCM.L	0.853
RMMC.L	0.842
UPGS.L	0.834
RWS.L	0.833
DGN.L	0.829

10 Labiausiai neigiamai susiję koreliacijos
CMET.L	-0.851
PEN.L	-0.827
CAMB.L	-0.818
EUZ.L	-0.804

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Destiny Pharma PLC Koreliacija - Valiuta/Žaliavos

0.65
( moderate )

0.53
( weak )

0.00
( neutral )

0.58
( weak )

-0.03
( neutral )

-0.55
( weak negative )

Destiny Pharma PLC Finansinės ataskaitos

Annual	2023
Pajamos:	£831 552
Bruto pelnas:	£831 552 (100.00 %)
EPS:	£-0.0624

FY	2023
Pajamos:	£831 552
Bruto pelnas:	£831 552 (100.00 %)
EPS:	£-0.0624

FY	2022
Pajamos:	£154 499
Bruto pelnas:	£142 171 (92.02 %)
EPS:	£-0.0926

FY	2021
Pajamos:	£0.00
Bruto pelnas:	£0.00 (0.00 %)
EPS:	£-0.0890

Financial Reports:

No articles found.

Destiny Pharma PLC

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Biofilm that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, oral mucosa, and ocular infection diseases. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; the University of Southampton; Aston University; the University of Sheffield; and Cardiff University and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.